PL2594279T3 - Peptydy chroniące tkanki i ich zastosowania - Google Patents

Peptydy chroniące tkanki i ich zastosowania

Info

Publication number
PL2594279T3
PL2594279T3 PL12175366T PL12175366T PL2594279T3 PL 2594279 T3 PL2594279 T3 PL 2594279T3 PL 12175366 T PL12175366 T PL 12175366T PL 12175366 T PL12175366 T PL 12175366T PL 2594279 T3 PL2594279 T3 PL 2594279T3
Authority
PL
Poland
Prior art keywords
tissue protective
protective peptides
peptides
tissue
protective
Prior art date
Application number
PL12175366T
Other languages
English (en)
Polish (pl)
Inventor
Anthony Cerami
Michael Brines
Thomas Coleman
Original Assignee
Araim Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Araim Pharmaceuticals, Inc. filed Critical Araim Pharmaceuticals, Inc.
Publication of PL2594279T3 publication Critical patent/PL2594279T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Tropical Medicine & Parasitology (AREA)
PL12175366T 2005-08-05 2006-08-07 Peptydy chroniące tkanki i ich zastosowania PL2594279T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US70574105P 2005-08-05 2005-08-05
US70627605P 2005-08-08 2005-08-08
US83173706P 2006-07-18 2006-07-18
EP06801051A EP1924276A4 (en) 2005-08-05 2006-08-07 Antiperspirant peptides and their uses
EP12175366.9A EP2594279B1 (en) 2005-08-05 2006-08-07 Tissue protective peptides and uses thereof
EP11163194.1A EP2371855B1 (en) 2005-08-05 2006-08-07 Tissue protective peptides and uses thereof

Publications (1)

Publication Number Publication Date
PL2594279T3 true PL2594279T3 (pl) 2018-03-30

Family

ID=37728020

Family Applications (3)

Application Number Title Priority Date Filing Date
PL12175366T PL2594279T3 (pl) 2005-08-05 2006-08-07 Peptydy chroniące tkanki i ich zastosowania
PL12175352T PL2540309T3 (pl) 2005-08-05 2006-08-07 Peptydy chroniące tkanki i ich zastosowanie
PL11163194T PL2371855T3 (pl) 2005-08-05 2006-08-07 Peptydy o działaniu ochronnym wobec tkanek

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL12175352T PL2540309T3 (pl) 2005-08-05 2006-08-07 Peptydy chroniące tkanki i ich zastosowanie
PL11163194T PL2371855T3 (pl) 2005-08-05 2006-08-07 Peptydy o działaniu ochronnym wobec tkanek

Country Status (25)

Country Link
US (7) US8071554B2 (enExample)
EP (5) EP1924276A4 (enExample)
JP (6) JP5274253B2 (enExample)
KR (7) KR101713368B1 (enExample)
CN (2) CN101378772B (enExample)
AU (1) AU2006278264B2 (enExample)
BR (1) BRPI0614529A8 (enExample)
CA (3) CA2982909A1 (enExample)
DK (3) DK2540309T3 (enExample)
EA (1) EA015672B1 (enExample)
ES (3) ES2653864T3 (enExample)
HU (3) HUE035655T2 (enExample)
IL (3) IL189287A (enExample)
IN (1) IN2014CN02050A (enExample)
LT (2) LT2540309T (enExample)
MX (3) MX339613B (enExample)
NO (1) NO20081112L (enExample)
NZ (1) NZ565937A (enExample)
PL (3) PL2594279T3 (enExample)
PT (3) PT2594279T (enExample)
SG (2) SG2014007868A (enExample)
SI (3) SI2594279T1 (enExample)
UA (1) UA100222C2 (enExample)
WO (1) WO2007019545A2 (enExample)
ZA (1) ZA201101890B (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US8653028B2 (en) 2005-04-29 2014-02-18 Rui Rong Yuan Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
US9585932B2 (en) * 2005-04-29 2017-03-07 Peter C. Dowling Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders
US9345745B2 (en) 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
ES2653864T3 (es) 2005-08-05 2018-02-09 Araim Pharmaceuticals, Inc. Péptidos protectores de tejido y usos de los mismos
US20090280094A1 (en) * 2006-06-07 2009-11-12 The University Of Tokushima Treatment of Ischemic Diseases Using Erythropoietin
EP2081956B1 (en) 2006-11-13 2013-03-20 Charité - Universitätsmedizin Berlin Method of cell culture and method of treatment comprising a vepo protein variant
CA2712757A1 (en) 2008-01-22 2009-07-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
AU2016203452B2 (en) * 2008-01-22 2018-02-22 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
AU2014203195B2 (en) * 2008-01-22 2016-03-31 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
US8791234B2 (en) * 2010-10-14 2014-07-29 Rutgers, The State University Of New Jersey Intestinal peptide targeting ligands
US9566349B2 (en) * 2010-10-14 2017-02-14 Rutgers, The State University Of New Jersey Intestinal peptide targeting ligands
CN102180948A (zh) * 2011-03-03 2011-09-14 复旦大学附属中山医院 一种具有肾脏保护作用的短肽及其制备方法和应用
CN102212111B (zh) * 2011-05-05 2014-04-30 中国人民解放军第三军医大学 小分子多肽和小分子多肽脂质体及其运用
WO2013016634A1 (en) * 2011-07-27 2013-01-31 Neumedicines, Inc. Use of il-12 to generate endogenous erythropoietin
WO2013042118A1 (en) * 2011-09-20 2013-03-28 A.A. Cash Technology Ltd Methods and devices for occluding blood flow to an organ
KR101148191B1 (ko) * 2011-09-27 2012-05-23 김후정 에리스로포이에틴-유래 펩타이드 및 그 용도
WO2013158871A1 (en) * 2012-04-20 2013-10-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of erythropoietin and derivatives for treating hypertension
MX2016000448A (es) * 2013-07-17 2016-05-12 Araim Pharmaceuticals Inc Péptidos y análogos peptídicos protectores de tejido para prevenir y tratar enfermedades y trastornos asociados con daño del tejido.
CN104744593A (zh) * 2013-12-25 2015-07-01 深圳先进技术研究院 一种抗肿瘤血管生成免疫复合肽及其制备方法和应用
US11039621B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039620B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US9622483B2 (en) 2014-02-19 2017-04-18 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
KR20150130616A (ko) * 2014-05-13 2015-11-24 (주)케어젠 피부상태 개선 활성을 갖는 펩타이드 및 이의 용도
CN105968172A (zh) * 2014-06-22 2016-09-28 马恒标 组织保护活性多肽sl2及其应用
MX391259B (es) * 2015-10-14 2025-03-21 X Therma Inc Composiciones y métodos para reducir la formación de cristales de hielo.
JP2019523633A (ja) 2016-04-29 2019-08-29 アライム ファーマシューティカルズ，インコーポレーテッド 組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド
KR102499651B1 (ko) 2016-11-10 2023-02-13 에이에스씨 리제니티 리미티드 에리트로포이에틴-유래 분자를 함유하는 국소 적용을 위한 미용 제형
EP3587443A4 (en) 2017-02-27 2021-02-17 Sylus Co., Ltd. USE OF ERYTHROPOIETIN PEPTIDE BY EFFECT ON CELL DAMAGE PREVENTION THEREOF
CN108503690B (zh) * 2017-02-28 2020-07-03 暨南大学 一种促进创伤后组织修复与再生的修复肽及其应用
WO2018157773A1 (zh) 2017-02-28 2018-09-07 暨南大学 一种促进创伤后组织修复与再生的修复肽及其应用
IL277689B2 (en) * 2018-04-08 2024-12-01 Brim Biotechnology Inc Application of pedf-derived short peptides in tendon healing
KR102300060B1 (ko) 2018-06-12 2021-09-08 주식회사 엘지에너지솔루션 2열 터미널 구조의 pcb 다이렉트 커넥터
BR112021004444A2 (pt) 2018-09-10 2021-06-01 Cold Spring Harbor Laboratory métodos para tratar pancreatite
CN112390877B (zh) * 2019-08-16 2022-10-04 董红燕 Pedf衍生多肽组合物及其在制备保护肺损伤药物中的应用
CN118255845B (zh) * 2022-12-27 2025-07-11 上海瑞吉康生物医药有限公司 相分离逆转多肽的变体及其应用

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
US4558006A (en) 1983-02-04 1985-12-10 Kirin-Amgen, Inc. A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin
US5051448A (en) 1984-07-24 1991-09-24 The Mclean Hospital Corporation GABA esters and GABA analog esters
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
US5498694A (en) 1989-05-25 1996-03-12 La Jolla Cancer Research Foundation Peptides of the cytoplasmic domain of integrin
DE3924746A1 (de) 1989-07-26 1991-01-31 Behringwerke Ag Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
WO1991004014A1 (en) 1989-09-21 1991-04-04 Synergen, Inc. Method for transporting compositions across the blood brain barrier
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US6063625A (en) * 1993-02-12 2000-05-16 Board Of Trustees Of Leland S, Stanford, Jr. University Regulated transcription of targeted genes and other biological events
US5559103A (en) 1993-07-21 1996-09-24 Cytel Corporation Bivalent sialyl X saccharides
US5571787A (en) 1993-07-30 1996-11-05 Myelos Corporation Prosaposin as a neurotrophic factor
US5700909A (en) 1993-07-30 1997-12-23 The Regents Of The University Of California Prosaposin and cytokine-derived peptides
WO1995021919A2 (en) * 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
ITFI940106A1 (it) * 1994-05-27 1995-11-27 Menarini Ricerche Sud Spa Molecola ibrida di formula gm-csf-l-epo o epo-l-gm-csf per la stimolaz ione eritropoietica
US5576423A (en) 1994-12-02 1996-11-19 Schering Corporation Antibodies to the slam protein expressed on activated T cells
TR199701557T2 (xx) * 1995-06-07 2002-06-21 Ortho Pharmaceutical Corporation Eritropoietin resept�r�ne ba�lanan bile�ikler ve peptidler.
JP2001524944A (ja) * 1997-03-05 2001-12-04 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 神経障害性疼痛の緩和方法
US7270809B2 (en) * 1997-07-14 2007-09-18 Bolder Biotechnology, Inc. Cysteine variants of alpha interferon-2
US7153943B2 (en) * 1997-07-14 2006-12-26 Bolder Biotechnology, Inc. Derivatives of growth hormone and related proteins, and methods of use thereof
IL145895A0 (en) 1999-04-13 2002-07-25 Kenneth S Warren Lab Modulation of excitable tissue function by peripherally administered erythropoietin
AU2001252650A1 (en) * 2000-04-28 2001-11-12 Effector Cell Institute Novel derivative of cell chemotactic factor
CN100528235C (zh) * 2000-12-20 2009-08-19 霍夫曼-拉罗奇有限公司 红细胞生成素共轭物
US20030072737A1 (en) 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
PA8536201A1 (es) 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
EP1357933A2 (en) * 2001-02-06 2003-11-05 MERCK PATENT GmbH Modified erythropoietin (epo) with reduced immunogenicity
IL158261A0 (en) * 2001-04-04 2004-05-12 Genodyssee New polynucleotides and polypeptides of the erythropoietin gene
KR100467751B1 (ko) * 2001-12-03 2005-01-24 씨제이 주식회사 생체내 에리스로포이에틴 활성이 증진된 융합단백질
US7300915B2 (en) * 2002-06-05 2007-11-27 The Regents Of The University Of California Use of erythropoietin and erythropoietin mimetics for the treatment of neuropathic pain
KR20060019501A (ko) 2002-07-01 2006-03-03 더 케네쓰 에스. 워렌 인스티튜트 인코포레이티드 응답 세포, 조직 및 기관을 보호, 회복 및 향상시키기위한 재조합 조직 보호 사이토카인 및 이를 코딩하는 핵산
KR100478455B1 (ko) 2002-08-19 2005-03-22 삼성전자주식회사 전자렌지
MXPA05002617A (es) 2002-09-09 2005-09-08 Warren Pharmaceuticals Inc Eritropoyetinas de accion prolongada que mantienen la actividad protectora de tejidos de la eritropoyetina endogena.
JP2006512300A (ja) * 2002-10-03 2006-04-13 エピミューン インコーポレイテッド Ｈｌａ結合ペプチド及びその使用
JP2004305006A (ja) * 2003-04-01 2004-11-04 Japan Science & Technology Agency 人工調製肺サーファクタント
ES2354304T3 (es) * 2003-04-25 2011-03-11 The University Of Pittsburgh Células derivadas del músculo (mdcs) para promover y potenciar la regeneración y reparación de nervios.
US7718363B2 (en) 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
BRPI0409650A (pt) 2003-09-09 2006-04-25 Warren Pharmaceuticals Inc métodos para regular o nìvel hematócrito e humanos, produtos de eritropoietina artificial, métodos para preparar um produto de eritropoietina e pra tratar anemia em pacientes em risco de dano no tecido, e, composição farmacêutica
WO2005032467A2 (en) 2003-09-29 2005-04-14 Warren Pharmaceuticals, Inc. Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
US20080227696A1 (en) * 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
WO2007010552A2 (en) 2005-03-17 2007-01-25 Serum Institute Of India Limited N- terminal peg conjugate of erythropoietin
US8653028B2 (en) 2005-04-29 2014-02-18 Rui Rong Yuan Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
US9345745B2 (en) 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
EP2377884A1 (en) 2005-05-10 2011-10-19 Neoloch Aps Neuritogenic peptides
EP1736481A1 (en) 2005-05-13 2006-12-27 Charite Universitätsmedizin-Berlin Erythropoietin variants
WO2006127910A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
ES2653864T3 (es) 2005-08-05 2018-02-09 Araim Pharmaceuticals, Inc. Péptidos protectores de tejido y usos de los mismos
SI2492355T1 (sl) 2007-11-29 2015-08-31 Molecular Health Gmbh Tkivno protektivni eritropoetinski receptor (nepor) in postopki uporabe
CA2712757A1 (en) 2008-01-22 2009-07-30 Araim Pharmaceuticals, Inc. Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
AU2009243187C1 (en) * 2008-04-28 2015-12-24 President And Fellows Of Harvard College Supercharged proteins for cell penetration
WO2011022056A2 (en) 2009-08-18 2011-02-24 Medical College Of Georgia Research Institute, Inc. PEPTIDE MODULATORS OF THE δPKC INTERACTION WITH THE D SUBUNIT OF F1FO ATP SYNTHASE/ATPASE AND USES THEREOF

Also Published As

Publication number Publication date
JP5274253B2 (ja) 2013-08-28
CA2618396A1 (en) 2007-02-15
DK2594279T3 (en) 2018-01-08
AU2006278264B2 (en) 2012-12-06
US20150152156A1 (en) 2015-06-04
MX339613B (es) 2016-06-02
SG2014007868A (en) 2014-05-29
JP2015134772A (ja) 2015-07-27
JP5918155B2 (ja) 2016-05-18
JP6158235B2 (ja) 2017-07-05
EP1924276A2 (en) 2008-05-28
SI2540309T1 (en) 2018-04-30
KR20080064800A (ko) 2008-07-09
PL2540309T3 (pl) 2018-03-30
KR20170027868A (ko) 2017-03-10
IL239695A0 (en) 2015-08-31
LT2540309T (lt) 2018-01-10
US10100096B2 (en) 2018-10-16
HUE035793T2 (en) 2018-05-28
CA2618396C (en) 2018-02-27
KR20180067735A (ko) 2018-06-20
HK1127751A1 (en) 2009-10-09
EP1924276A4 (en) 2009-07-22
WO2007019545A2 (en) 2007-02-15
JP2018134084A (ja) 2018-08-30
UA100222C2 (uk) 2012-12-10
JP2016196480A (ja) 2016-11-24
US8673861B2 (en) 2014-03-18
WO2007019545A3 (en) 2008-10-02
SI2371855T1 (sl) 2015-11-30
ES2550055T3 (es) 2015-11-04
NO20081112L (no) 2008-05-05
PT2540309T (pt) 2017-12-29
IL261346A (en) 2018-10-31
EP2371855B1 (en) 2015-07-22
US8071554B2 (en) 2011-12-06
CN101378772A (zh) 2009-03-04
MX2008001509A (es) 2008-04-04
EP2540309B1 (en) 2017-11-22
HUE035655T2 (en) 2018-05-28
KR20130080481A (ko) 2013-07-12
JP2020078317A (ja) 2020-05-28
ES2653790T3 (es) 2018-02-08
US9340598B2 (en) 2016-05-17
EP2540309A3 (en) 2013-05-29
ES2653864T3 (es) 2018-02-09
KR20190084136A (ko) 2019-07-15
US20140323401A1 (en) 2014-10-30
AU2006278264A1 (en) 2007-02-15
CA2982909A1 (en) 2007-02-15
CA3079319A1 (en) 2007-02-15
DK2371855T3 (en) 2015-09-21
LT2594279T (lt) 2018-01-10
ZA201101890B (en) 2012-12-27
US20160244498A1 (en) 2016-08-25
CN101378772B (zh) 2013-12-04
PL2371855T3 (pl) 2015-12-31
CN103724418B (zh) 2018-03-06
EP2594279A1 (en) 2013-05-22
KR101713368B1 (ko) 2017-03-07
IL189287A0 (en) 2008-06-05
EP2540309A2 (en) 2013-01-02
PT2371855E (pt) 2015-11-03
EA200800536A1 (ru) 2009-02-27
EP2371855A1 (en) 2011-10-05
US8716245B2 (en) 2014-05-06
NZ565937A (en) 2011-09-30
BRPI0614529A2 (pt) 2011-08-09
JP2009508471A (ja) 2009-03-05
MX364100B (es) 2019-04-12
IL189287A (en) 2015-07-30
US20120142595A1 (en) 2012-06-07
KR20200072568A (ko) 2020-06-22
EP3363451A1 (en) 2018-08-22
SI2594279T1 (en) 2018-04-30
EA015672B1 (ru) 2011-10-31
JP2013126995A (ja) 2013-06-27
SG10201805825SA (en) 2018-08-30
JP6491621B2 (ja) 2019-03-27
US20090221482A1 (en) 2009-09-03
US20120264682A1 (en) 2012-10-18
KR20180116475A (ko) 2018-10-24
BRPI0614529A8 (pt) 2016-07-12
DK2540309T3 (en) 2018-01-08
PT2594279T (pt) 2017-12-29
EP2594279B1 (en) 2017-11-22
US20190016769A1 (en) 2019-01-17
IN2014CN02050A (enExample) 2015-05-29
CN103724418A (zh) 2014-04-16
KR101626153B1 (ko) 2016-06-01
HUE026444T2 (en) 2016-05-30

Similar Documents

Publication Publication Date Title
IL261346A (en) Tissue protective peptides and their uses
IL187617A0 (en) Lkktet and/or lkktnt peptide compositions and methods
IL185308A0 (en) Replikin peptides and uses thereof
EP1976864A4 (en) NEW PEPTIDE AND ITS USE
IL189252A0 (en) Dihydroxyanthraquinones and their use
EP1967123A4 (en) ENDOSCOPE AND ENDOSCOPE SYSTEM
IL195525A0 (en) Replikin peptides and uses thereof
GB0516069D0 (en) Pharmaceutical and use thereof
ZA200801874B (en) Antigenic peptides and their use
GB0604187D0 (en) Peptide and uses thereof
IL185575A0 (en) Benzoxazocines and their therapeutic use
IL188310A0 (en) Thrombospondin-1 derived peptides and treatment methods
GB0526120D0 (en) Therapeutic peptides
ZA200800566B (en) Therapeutic peptides and vaccines
IL192800A0 (en) Fgf2-binding peptides and uses thereof
GB0617564D0 (en) Peptides and methods
GB0517813D0 (en) Peptides and uses thereof
GB0508726D0 (en) Polypeptide, vaccine and use thereof
GB0503093D0 (en) Ricin-binding peptide and methods for use thereof
GB0612873D0 (en) Isolated peptides and uses thereof
GB0425731D0 (en) Isolated peptides and uses thereof
GB0520144D0 (en) Surgical pin protector and system
HK1116833A (en) Replikin peptides and uses thereof
GB0507566D0 (en) Skin protection
HK1110862A (en) Antigenic peptides and their use